Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

September 7, 2022

Study Completion Date

March 20, 2023

Conditions
Syphilis
Interventions
DRUG

Benzathine Penicillin

BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.

Trial Locations (10)

15213

Magee Women's Hospital of UPMC - Reproductive Infectious Disease Research, Pittsburgh

21224

Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore

27157

Wake Forest Baptist Health - Infectious Diseases, Winston-Salem

30308

Emory University Hospital Midtown - Emory Clinic Infectious Diseases, Atlanta

35294

University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham

46202

Indiana University School of Medicine - Infectious Diseases, Indianapolis

70119

Louisiana State University Health Sciences Center, New Orleans

02115

Fenway Health - The Fenway Institute, Boston

27701-3720

University of North Carolina School of Medicine - Center for Infectious Diseases, Durham

98104-2433

University of Washington - Harborview Medical Center - Center for AIDS and STD, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03637660 - Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection | Biotech Hunter | Biotech Hunter